Expression of nuclear transcription factor E2F2 protein in ovarian serous tumor tissue and its clinical significance

Objective:To investigate the expression of nuclear transcription factor E2F2 protein in ovarian serous tumors and its clinical significance.Methods:Immunohistochemical staining was used to determine the expression of E2F2 protein in 33 cases of ovarian serous cystadenocarcinama,11 cases of borderline serous cystadenoma,13 cases of serous adenomas and 12 cases of normal ovarian tissues.Results:The positive rates of E2F2 protein in serous cystadenocarcinama,borderline serous cystadenoma,serous adenomas and normal ovarian tissues were 72.73%,54.55%,15.38%,8.3%,respectively.The positive rates were compared among the four groups,and it present a significant differences(P0.05)between serous cystadenocarcinama,borderline serous cystadenoma and serous adenomas,normal ovarian tissues respectivly,but no significant differences were observed between serous cystadenocarcinama and borderline serous cystadenoma,serous adenomas and normal tissues(P0.05).In serous cystadenocarcinama,the positive rates of E2F2 protein were increasing with rising of pathologic staging(P0.05),but no relationship with pathologic grade,lymphonodes(P0.05).In serous cystadenocarcinama,the positive level of E2F2 protein was increasing with the rising of pathologic staging and the depressing of pathologic grade(P0.05),but no significant differences between it and lymphonodes(P0.05).Conclusion:The expressions of E2F2 protein were significantly increased in serous cystadenocarcinama and borderline serous cystadenoma,and the expressions of E2F2 protein were correlated with FIGO stage and differentiation grade.E2F2 might play a promoting role in the genesis and progression of ovarian carcinoma.